A single-arm, open-label, Phase I clinical trial evaluating the safety and efficacy of TX103 CAR-T cells in subjects with TX103-positive advanced solid tumors
Latest Information Update: 28 Oct 2024
At a glance
- Drugs TX 103 (Primary) ; TX 103 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 18 Jul 2024 New trial record